Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | FRK | P42685 | 2/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 3/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.35 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25184191 | 0.82 | MAPK9 (0.47) | EGFRMAPK9MAP4K4FRKCSNK1A1 | |
| SCHEMBL2650530 | 0.79 | MAP4K4 (0.43) | EGFRMAPK9MAP4K4FRKCSNK1A1 | |
| SCHEMBL1444789 | 0.78 | EGFR (0.42) | EGFRMAPK9MAP4K4FRKCSNK1A1 | |
| SCHEMBL2649276 | 0.77 | KDM4E (0.45) | POLBMEN1MAPTHPGDKMT2A | |
| SCHEMBL2652043 | 0.76 | ALOX5AP (0.42) | POLBCASP6AMY1AMEN1MAPT | |
| SCHEMBL2648431 | 0.76 | CASP6 (0.36) | EGFRMAPK9MAP4K4FRKCSNK1A1 | |
| SCHEMBL30141958 | 0.74 | NPC1 (0.46) | EGFRMAPK9MAP4K4FRKCSNK1A1 | |
| SCHEMBL2650141 | 0.74 | IMPDH2 (0.49) | POLBMAPK14MAPTSMN1; SMN2 | |
| SCHEMBL28296072 | 0.74 | NPC1 (0.46) | EGFRMAPK9MAP4K4FRKCSNK1A1 | |
| SCHEMBL2653973 | 0.74 | GABRG2 (0.43) | MEN1MAPTHPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343788-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-6960598-B2 | (1,8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | MERCK SHARP & DOHME LTD. | 2005-11-01 | — | — | US | disclosed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | disclosed |
| US-20040171633-A1 | (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | MERCK SHARP & DOHME LTD. (GB) | 2004-09-02 | — | — | US | disclosed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1343788-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003006464-A1 | (1,8) NAPHTHYRIDINES AS GABA LIGANDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES | MERCK SHARP & DOHME LIMITED (GB) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002038568-A1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | GABRA2, GABRA5, GABRA1 | EGFR 2633/4885MAPK9 4334/4885MAP4K4 1292/4885 |
| US-20040171633-A1 | (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses | GABRA1, GABRA4, GABRA6 | EGFR 2144/4885MAPK9 3995/4885MAP4K4 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.